Hôpital Lariboisière Fernand Widal, Assistance Publique-Hôpitaux de Paris, Paris, France.
Université de Paris, Paris, France.
Eur J Heart Fail. 2022 Jan;24(1):219-226. doi: 10.1002/ejhf.2357. Epub 2021 Oct 21.
Hospitalization for acute heart failure (HF) is followed by a vulnerable time with increased risk of readmission or death, thus requiring particular attention after discharge. In this study, we examined the impact of intensive, early follow-up among patients at high readmission risk at discharge after treatment for acute HF.
Hospitalized acute HF patients were included with at least one of the following: previous acute HF < 6 months, systolic blood pressure ≤ 110 mmHg, creatininaemia ≥ 180 µmol/L, or B-type natriuretic peptide ≥ 350 pg/mL or N-terminal pro B-type natriuretic peptide ≥ 2200 pg/mL. Patients were randomized to either optimized care and education with serial consultations with HF specialist and dietician during the first 2-3 weeks, or to standard post-discharge care according to guidelines. The primary endpoint was all-cause death or first unplanned hospitalization during 6-month follow-up. Among 482 randomized patients (median age 77 and median left ventricular ejection fraction 35%), 224 were hospitalized or died. In the intensive group, loop diuretics (46%), beta-blockers (49%), angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (39%) and mineralocorticoid receptor antagonists (47%) were titrated. No difference was observed between groups for the primary endpoint (hazard ratio 0.97; 95% confidence interval 0.74-1.26), nor for mortality at 6 or 12 months or unplanned HF rehospitalization. Additionally, no difference between groups according to age, previous HF and left ventricular ejection fraction was found.
In high-risk HF, intensive follow-up early post-discharge did not improve outcomes. This vulnerable post-discharge time requires further studies to clarify useful transitional care services.
急性心力衰竭(HF)住院后是一个脆弱时期,再入院或死亡风险增加,因此出院后需要特别关注。本研究旨在探讨对急性 HF 治疗后出院时具有高再入院风险的患者进行强化、早期随访的影响。
纳入至少符合以下一项标准的住院急性 HF 患者:<6 个月前发生急性 HF、收缩压≤110mmHg、肌氨酸酐≥180µmol/L 或 B 型利钠肽≥350pg/mL 或 N 末端 B 型利钠肽≥2200pg/mL。患者被随机分为优化护理和教育组,在前 2-3 周内接受 HF 专家和营养师的系列会诊,或根据指南接受标准出院后护理。主要终点是 6 个月随访期间的全因死亡或首次计划外住院。在 482 名随机分组的患者(中位年龄 77 岁,中位左心室射血分数 35%)中,有 224 名患者住院或死亡。在强化组中,利尿剂(46%)、β受体阻滞剂(49%)、血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂(39%)和盐皮质激素受体拮抗剂(47%)进行滴定。主要终点两组间无差异(风险比 0.97;95%置信区间 0.74-1.26),6 个月或 12 个月时的死亡率或计划外 HF 再入院也无差异。此外,根据年龄、既往 HF 和左心室射血分数,两组间也未发现差异。
在高危 HF 中,出院后早期强化随访并未改善结局。这一脆弱的出院后时期需要进一步研究来明确有用的过渡性护理服务。